This site is intended for US
healthcare professionals only.

Important Safety Information Prescribing Information

EXPERT INSIGHTS

RESOURCES

See what the experts are saying about treatment with NINLARO® (ixazomib)

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

NOW PLAYING

The role of combination therapy in the long-term* treatment of multiple myeloma

  • Dr. Noga and Dr. Palumbo are employees of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
NOW PLAYING

The importance of long-term* proteasome inhibition in multiple myeloma

  • Dr. Vescio is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
NOW PLAYING

Oral proteasome inhibition in the evolving multiple myeloma treatment landscape

  • Dr. Niesvizky is a paid consultant of Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
  • *Defined as treatment to progression or unacceptable toxicity.
  • This content is intended for informational purposes only and is not a substitute for your clinical knowledge or professional judgment.